Insider Buying: Spero Therapeutics, Inc. (NASDAQ:SPRO) Major Shareholder Acquires $114,650.31 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) major shareholder Aquilo Capital Management, Llc bought 8,867 shares of the stock in a transaction dated Monday, January 10th. The stock was purchased at an average cost of $12.93 per share, with a total value of $114,650.31. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Aquilo Capital Management, Llc also recently made the following trade(s):

  • On Friday, October 29th, Aquilo Capital Management, Llc bought 150,000 shares of Spero Therapeutics stock. The stock was purchased at an average cost of $17.53 per share, with a total value of $2,629,500.00.

Shares of Spero Therapeutics stock opened at $13.20 on Friday. Spero Therapeutics, Inc. has a 12 month low of $11.69 and a 12 month high of $22.24. The business has a fifty day simple moving average of $14.59 and a 200 day simple moving average of $15.74. The stock has a market cap of $426.68 million, a PE ratio of -4.94 and a beta of 1.54.

Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Wednesday, November 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). Spero Therapeutics had a negative net margin of 454.11% and a negative return on equity of 69.84%. The business had revenue of $3.06 million during the quarter, compared to analyst estimates of $3.00 million. During the same period in the previous year, the firm posted ($0.86) earnings per share. As a group, research analysts predict that Spero Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on the company. Zacks Investment Research raised Spero Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Wednesday. Oppenheimer cut Spero Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, October 1st.

A number of large investors have recently bought and sold shares of SPRO. Granahan Investment Management Inc. MA grew its stake in Spero Therapeutics by 67.0% in the third quarter. Granahan Investment Management Inc. MA now owns 555,614 shares of the company’s stock valued at $10,229,000 after acquiring an additional 222,975 shares during the period. Royal Bank of Canada grew its stake in Spero Therapeutics by 8,249.7% in the third quarter. Royal Bank of Canada now owns 180,102 shares of the company’s stock valued at $3,316,000 after acquiring an additional 177,945 shares during the period. Vanguard Group Inc. grew its stake in Spero Therapeutics by 15.4% in the second quarter. Vanguard Group Inc. now owns 1,276,790 shares of the company’s stock valued at $17,824,000 after acquiring an additional 170,094 shares during the period. Brandywine Global Investment Management LLC acquired a new position in Spero Therapeutics in the third quarter valued at about $1,075,000. Finally, Geode Capital Management LLC grew its stake in Spero Therapeutics by 13.8% in the second quarter. Geode Capital Management LLC now owns 413,761 shares of the company’s stock valued at $5,776,000 after acquiring an additional 50,150 shares during the period. 59.47% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A.

Featured Article: Asset Allocation and Your Retirement

Insider Buying and Selling by Quarter for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.